As Head of Digital Health across all of Oncology R&D at AstraZeneca, my focus is on leveraging emerging technology to improve patient care and expand the evidence base for oncology treatments. I have deep experience in developing and implementing innovative patient relevant evidence strategies across tumour types within oncology drug development and rare disease.

I believe that reliable empirical evidence is the backbone of empowered decision- making. I’m most passionate about measuring the impact of cancer, and the tolerability of anti-cancer therapies, on patients in a rigorous and reliable way. This work is critical in providing patients with the best evidence to make important healthcare decisions, such as treatment choice, following a cancer diagnosis.

As founder of the strategic advising group, Patient Relevant Evidence, I work to optimize patient-centric evidence generation for non-profit advocacy entities and academic consortiums. This includes recent work with the European organisation for the Treatment of cancer focused on the development of international standards in analysing patient-reported outcomes and quality of life endpoints for cancer clinical trials for regulatory evaluation.

Most recently, I led Roche/Genentech’s oncology patient-centred outcomes research group, in which I was responsible for novel Food and Drug Administration (FDA) patient-reported outcomes labelling claims on products for lymphoma and haemophilia. Additionally, I developed the Symptoms in Lung Cancer tool while at Roche which was included in multiple front-line Phase 3 registration trials. Prior to that, I was a Director in Health Economics and Outcomes Research at Pfizer Oncology responsible for outcomes research strategy for the development pipeline.

Over the course of my career, I have been a contributor and advisor to numerous policy initiatives such as the landmark 21st Century Cures legislation. I’ve participated in various FDA workshops and legislative briefings about the importance of the patient experience in drug development. I also served as co-chair of the Critical Path Institute’s Non-Small Cell Lung Cancer Working Group. My work has been recognised by Former Vice President Biden’s Cancer Moonshot Initiative.

I completed my Masters of Public Health from the University of Connecticut School of Medicine with concentrations in Epidemiology and Outcomes Research. 

 

Digital health has the potential to reimagine healthcare. By quantifying the patient voice, we can strengthen decision-making across the product development lifecycle, improve the overall patient experience and help to empower patients as equal partners in their own care.

Alicyn Campbell Head of Digital Health, Oncology R&D

CURRENT ROLE

Head of Digital Health, Oncology R&D

2019 – present

Founder at Patient Relevant Evidence, LLC serving in a strategic advising role to optimize patient-centric evidence generation for non-profit advocacy entities and academic consortiums

2019 – present

Scientific advisory board member at CareVive Systems Inc.

2012 – 2019

Served as Global Head, Patient Reported Outcomes for Oncology at Genentech leading a diverse team of outcomes research scientists to quantify the patient’s voice in clinical trials and better understand the impact of new therapies

Featured publications

Use of Patient-Reported Outcomes to Understand and Measure the Patient Experience of Novel Cell and Gene Therapies.

L Lasiter, A Campbell, E Basch, S Hudgens, M Stewart, J Wu, A Leahy, J Allen. Ther Innov Regul Sci. 2020 June 22. Published online ahead of print 

https://pubmed.ncbi.nlm.nih.gov/32572771/

 

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium

C Coens, M Pe, AC Dueck, J Sloan, E Basch, M Calvert, A Campbell, et al. Lancet Oncol. 2020 Feb. 21(2): e83-e96

https://pubmed.ncbi.nlm.nih.gov/32007209/

 

Improving Attribution of Adverse Events in Oncology Clinical Trials.

GC George, PC Barata, A Campbell, et al. Cancer Treatment Reviews. 2019 June. 76:33 – 40

https://doi.org/10.1016/j.ctrv.2019.04.004

 

Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials.

PC Trask, AC Dueck, E Piault, A Campbell. Clin Trials. 2018 Dec. 15(6):616-623

https://pubmed.ncbi.nlm.nih.gov/30230365/

 

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

M Pe, L Dorme, C Coens, E Basch, M Calvert, A Campbell, et al. Lancet Oncol. 2018 Sept. 19(9): e459-e469

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30418-2/fulltext

 

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.

A Bottomley, M Pe, J Sloan, E Basch, F Bonnetain, M Calvert, A Campbell, et al. Clin Trials. 2018 Dec. 15(6): 624-630

https://pubmed.ncbi.nlm.nih.gov/30141714/

 

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

A Bottomley, M Pe, J Sloan, E Basch, F Bonnetain, M Calvert, A Campbell, et al. Lancet Oncol. 2016 Nov. 17(11): e510-e514

https://pubmed.ncbi.nlm.nih.gov/27769798/

 

Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab.

C Theodore-Oklota, L Humphrey, C Wiesner, G Schnetzler, S Hudgens, A Campbell. Patient Prefer Adherence. 2016 Sep 13. 10:1767-1776

https://pubmed.ncbi.nlm.nih.gov/27695295/

 

Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.

K Park, BC Cho, DW Kim, MJ Ahn, SY Lee, D Gernhardt, I Taylor, A Campbell, et al. J. Thorac Oncol. 2014 Oct. 9(10):1523-31

https://pubmed.ncbi.nlm.nih.gov/25521398/

 

Health-Related Quality of Life in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus Pemetrexed Maintenance Therapy in AVAPERL.

A Rittmeyer, V Gorbunova, A Vikstrom, A Scherpereel, JO Kim, MJ Ahn, A Chella, C Chouaid, A Campbell, F Barlesi. J. Thorac Oncol. 2013 Nov. 8(100):1409-16

https://pubmed.ncbi.nlm.nih.gov/24077452/